Stockscreener 앱 받기
0.2462
2.03%
-0.0051
시간 외 거래:
.26
0.0138
+5.61%
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News
Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News
A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com
Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com
CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com
Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com
Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Applied Dna Sciences Inc (APDN)’s Financial Health - DWinneX
CEL-SCI (NYSE:CVM) Coverage Initiated by Analysts at StockNews.com - Defense World
Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com
US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI
CEL-SCI to seek Saudi approval for cancer treatment - Investing.com
CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com
CEL-SCI's Cancer Drug Eyes Breakthrough Status in Saudi Arabia as MENA Cancer Cases Set to Double - Stock Titan
Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX
Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News
An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com
Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com
Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa
Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia
Cel-Sci Corp’s Market Journey: Closing Weak at 0.24, Down -0.08 - DWinneX
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Yahoo Finance
CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa
Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register
CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com
CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan
CEL-SCI advances in head and neck cancer treatment study - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance
CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market - Stock Titan
Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register
Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan
CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World
CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
5.24%
자본화:
|
볼륨(24시간):